Search Results - "QUECKE, H"

Refine Results
  1. 1

    Effects of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion by Sebastian, M., Jaeger, M., Kiewe, P., Schuette, W., Wiewrodt, R., Lindhofer, H., Mueller, B., Friccius-Quecke, H., Friccius- Quecke, H., Schmittel, A.

    Published in Journal of clinical oncology (20-06-2007)
    “…Abstract only 3046 Background: The trifunctional antibody catumaxomab specifically binds EpCAM+ tumor cells, CD3+ T lymphocytes and accessory cells via FcγR…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study by Jäger, M., Schoberth, A., Theissen, B., Hess, J., Friccius-Quecke, H., Lindhofer, H.

    Published in Journal of clinical oncology (20-05-2009)
    “…Abstract only 3029 Background: Treatment with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab efficiently eliminates tumor cells from the…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites by Bokemeyer, C., Heiss, M., Gamperl, H., Linke, R., Schulze, E., Friccius-Quecke, H., Lindhofer, H., Parsons, S.

    Published in Journal of clinical oncology (20-05-2009)
    “…Abstract only 3036 Background: As a targeted immunotherapy, the trifunctional antibody catumaxomab specifically binds to epithelial cell-adhesion molecule…”
    Get full text
    Journal Article
  7. 7
  8. 8

    Treatment of non-small cell lung cancer (NSCLC) patients with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study by Passlick, B., Schmittel, A., Friccius-Quecke, H., Kanniess, F., Wiewrodt, R., Lindhofer, H., Jaeger, M., Sebastian, M.

    Published in Journal of clinical oncology (20-06-2006)
    “…Abstract only 2540 Background: Catumaxomab is a trifunctional monoclonal antibody with binding specificities to human EpCAM, human CD3 and Fc gamma receptor…”
    Get full text
    Journal Article
  9. 9

    Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study by Sebastian, M., Schuette, W., Schneller, F., Nilius, G., Lodziewski, S., Passlick, B., Hoffken, G., Friccius-Quecke, H., Jaeger, M., Schmittel, A.

    Published in Journal of clinical oncology (20-06-2006)
    “…Abstract only 2548 Background: The trifunctional antibody catumaxomab specifically binds EpCAM + tumor cells, CD3+ T lymphocytes and accessory cells via the…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20